Search research articles
Contact Us
Filters
Showing results (111-120 of 133) with videos related to
Page
of 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
A Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C A Gomez-Roca, A Italiano, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
J-Y Blay, C Schiffler, O Bouché, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2017
Improved survival using specialized multidisciplinary board in sarcoma patients
J-Y Blay, P Soibinet, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2012
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE
J Thariat, T Schouman, A Brouchet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
A Bayle, L Belcaid, M Aldea, et al.
ESMO Open
|
November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanoma
J Y Blay, C Cropet, S Mansard, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 133) with videos related to
Sort By:
Page
of 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
A Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C A Gomez-Roca, A Italiano, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
J-Y Blay, C Schiffler, O Bouché, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2017
Improved survival using specialized multidisciplinary board in sarcoma patients
J-Y Blay, P Soibinet, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2012
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE
J Thariat, T Schouman, A Brouchet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
A Bayle, L Belcaid, M Aldea, et al.
ESMO Open
|
November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanoma
J Y Blay, C Cropet, S Mansard, et al.
Page
of 14